Search

Displaying results 4971 - 4980 of 7540 in total
  1. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. … Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

  2. Drug

    Meglutol

    go.drugbank.com/drugs/DB04377
    Experimental

    It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which

  3. Drug

    Putrescine

    go.drugbank.com/drugs/DB01917
    Investigational

    Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. Putrescine is a solid. This compound belongs to the polyamines.

  4. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Droloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity.[L34184] … Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity

  5. Drug

    Thonzylamine

    go.drugbank.com/drugs/DB11235
    Approved

    Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with DB04837 or DB00388 for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

  6. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973] … OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA).

  7. Drug

    Eflepedocokin alfa

    go.drugbank.com/drugs/DB16366
    Investigational

    [A225706, L27661] It is being developed by Evive Biotech (previously known as Generon BioMed Inc).[L27666] … Eflepedocokin alfa is a recombinant IL-22-Fc fusion protein manufactured in Chinese hamster ovary cells that is composed of 2 human interleukin 22 (IL-22) molecules linked to an immunoglobulin constant

    Synonyms: F-652 (RECOMBINANT FUSION PROTEIN CONSISTING OF TWO HUMAN INTERLEUKIN-22 (IL-22) MOLECULES LINKED TO AN IMMUNOGLOBULIN CONSTANT REGION (IGG2-FC))
  8. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  9. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]

  10. Drug

    Survodutide

    go.drugbank.com/drugs/DB18989
    Investigational

    Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT